Browse the corpus

Lymphedema is a chronic condition characterized by swelling, typically in the limbs, resulting from impaired lymphatic drainage. This condition most commonly occurs after cancer treatment, particularly when lymph nodes are removed or irradiated, but it can also arise from infections, injuries, or congenital abnormalities. Risk factors include obesity, limited mobility, and recurrent infections. Management focuses on early recognition, infection prevention, meticulous skin care, exercise, weight management, and compression garments. Effective care relies on patient education, self-management techniques such as manual lymphatic drainage, and a multidisciplinary approach involving clinicians, certified lymphedema therapists, nurses, physical and occupational therapists, pharmacists, and mental health professionals to address physical and psychosocial needs. Clinicians participating in this course can expect a comprehensive understanding of the pathophysiology, risk factors, and clinical presentation of lymphedema, along with evidence-based strategies for prevention, early detection, and management. They learn how to implement patient-centered interventions, coordinate care within an interprofessional team, and provide education to empower patients in self-care. Additionally, the course emphasizes recognizing complications, optimizing adherence to therapy, and addressing the psychosocial impacts of lymphedema, ultimately equipping clinicians to improve patient outcomes, enhance safety, and foster long-term quality of life for individuals with this condition. Objectives: Identify the pathophysiology of lymphedema, including lymphatic dysfunction and tissue remodeling. Evaluate the clinical presentation of lymphedema, including anatomical distribution, staging criteria, early versus advanced signs, and diagnostic distinctions from other causes of edema. Implement evidence-based and emerging treatment strategies, such as complete decongestive therapy, surgical approaches, compression therapy, and novel lymphangiogenic interventions. Communicate the importance of interdisciplinary care coordination, including early referral to certified lymphedema specialists and collaborative management involving clinicians, nurses, therapists, and patient education strategies to optimize outcomes. Access free multiple choice questions on this topic.

The lymphatic system consists of initial capillaries, collecting vessels, trunks, and lymph nodes that transport lymph, a fluid rich in proteins, immune cells, lipids, and metabolic waste. Superficial and deep lymphatic networks are connected by perforating vessels that traverse fascial layers, maintaining tissue fluid balance and immune surveillance.[1] Lymphedema is a chronic, progressive condition caused by impaired lymphatic drainage, leading to the abnormal accumulation of protein-rich lymphatic fluid in the interstitial tissues. When lymphatic transport capacity is exceeded, persistent edema triggers inflammation and progressive tissue remodeling, resulting in functional decline and long-term morbidity.[2] Lymphedema is classified as primary, due to congenital or genetic abnormalities in lymphatic development, or secondary, arising from acquired injury or obstruction. Secondary causes include surgery, radiation therapy, infection, trauma, and malignancy, with limb involvement most often seen following oncologic treatment.[3][4] Although extremities are most commonly affected, the head and neck, trunk, or genitalia can also be involved, leading to cosmetic deformity, psychological distress, and impaired function.[3] Clinically, patients present with swelling, heaviness, discomfort, reduced mobility, skin thickening, and difficulty wearing clothing. Complications such as recurrent infections and progressive decline in quality of life frequently occur without timely intervention.[4]

Lymphedema develops when lymphatic drainage is disrupted, causing progressive accumulation of protein-rich interstitial fluid, chronic inflammation, and soft tissue remodeling. This condition is classified as primary, resulting from congenital or genetic lymphatic abnormalities, or secondary, due to acquired lymphatic injury or obstruction. Although the true prevalence of inherited primary lymphedema is uncertain, estimates vary widely.[5] Primary Lymphedema This rare form arises from developmental malformations such as lymphatic hypoplasia, aplasia, or hyperplasia, which may occur in isolation or within syndromic disorders.[6][7][8] This type is further categorized by age of onset: congenital (birth/infancy), praecox (puberty to early adulthood, as in Meige disease and representing ~94% of cases), and tarda (onset after age 35).[6][7] Mutations in genes including FLT4 (vascular endothelial growth factor receptor 3 [VEGF]) and FOXC2 disrupt lymphangiogenesis and underlie many familial cases. Syndromic causes include Turner, Noonan, Klippel-Trénaunay-Weber, and Hennekam lymphangiectasia–lymphedema syndromes.[7] Turner syndrome commonly presents with neonatal pedal edema, with severity linked to specific karyotype abnormalities.[6][7] Hennekam syndrome, an autosomal recessive lymphatic dysplasia caused by CCBE1 or FAT4 mutations, manifests with intestinal and pulmonary lymphangiectasia and may include recurrent pericardial effusions, highlighting its systemic nature.[7] Secondary Lymphedema Far more common, secondary lymphedema results from acquired lymphatic injury, obstruction, or overload.[9] Worldwide, lymphatic filariasis (Wuchereria bancrofti) remains the leading cause in tropical and subtropical regions. In developed countries, cancer therapy–related lymphedema predominates, typically after lymph node dissection, radiation, or tumor infiltration.[8][9] High-risk malignancies include breast, gynecologic, genitourinary, and head and neck cancers; a meta-analysis found lymphedema rates up to 90% after multimodal head and neck cancer treatment with radiation and extensive nodal dissection.[10][11]

Far more common, secondary lymphedema results from acquired lymphatic injury, obstruction, or overload.[9] Worldwide, lymphatic filariasis (Wuchereria bancrofti) remains the leading cause in tropical and subtropical regions. In developed countries, cancer therapy–related lymphedema predominates, typically after lymph node dissection, radiation, or tumor infiltration.[8][9] High-risk malignancies include breast, gynecologic, genitourinary, and head and neck cancers; a meta-analysis found lymphedema rates up to 90% after multimodal head and neck cancer treatment with radiation and extensive nodal dissection.[10][11] Axillary web syndrome (AWS), palpable cord-like axillary bands after lymphadenectomy, significantly increases the risk of breast cancer–related lymphedema. A 2024 meta-analysis demonstrated higher lymphedema incidence in patients with AWS, reflecting shared mechanisms of lymphatic disruption and inflammation. Lymph node dissection and adjuvant radiation act independently and synergistically to impair lymphatic drainage.[12] Risk factors for cancer-related lymphedema include the extent of surgery, radiation dose, high body mass index (BMI), infection history, and medical comorbidities. Preventive strategies such as sentinel lymph node biopsy and emerging microsurgical techniques can reduce lymphatic injury.[13] Other nononcologic causes include trauma, chronic venous insufficiency, inflammatory skin disease, and obesity. The Lymphedema Impact and Prevalence International (LIMPRINT) study confirmed a strong link between elevated BMI and chronic lower-limb edema, with higher BMI correlating with more severe disease and functional decline.[14]

Lymphedema is a major but underrecognized global health challenge, affecting an estimated 140 to 250 million people worldwide. Reliable incidence data remain limited because of underdiagnosis, nonstandardized diagnostic criteria, and inconsistent terminology across clinical settings. In breast cancer survivors alone, 6% to 30% develop clinically significant arm lymphedema after axillary surgery despite advances in surgical and radiation techniques.[4] Primary Lymphedema Primary lymphedema is rare, affecting about 1 in 100,000 individuals and representing less than 10% of cases in the United States.[3][4] This type typically presents in adolescence or early adulthood and may occur sporadically or within familial clusters.[3][4] Congenital lymphedema, as seen in Turner syndrome, can manifest in infancy.[6] Secondary Lymphedema Accounting for more than 90% of global cases, secondary lymphedema results from acquired lymphatic injury or obstruction.[11] In the United States, recent estimates suggest 8 to 10 million affected individuals—roughly 3% of the population—a marked rise from older estimates of 1 in 1000.[11] Worldwide, lymphatic filariasis remains the leading cause in tropical and subtropical regions, whereas in high-income countries, cancer therapy is the predominant etiology. Incidence varies by cancer type, treatment modality, and the extent of lymphatic disruption.[5][7] Cancer-Related Lymphedema Population-based data show the highest lymphedema rates following gynecologic, breast, and genitourinary cancers, emphasizing the need for disease-specific surveillance. Among breast cancer survivors, 10% to 40% develop lymphedema, with risk highest after axillary lymph node dissection and radiation compared with sentinel lymph node biopsy alone. Gynecologic cancer patients undergoing pelvic lymphadenectomy and radiation face a 20% to 40% risk, with some series reporting up to 37% incidence in the first year posttreatment.[7] Head and neck cancer patients treated with multimodality therapy experience lymphedema rates as high as 90%, often involving the face, neck, and intraoral tissues.[15] Sex-Based Differences and Population Trends

Population-based data show the highest lymphedema rates following gynecologic, breast, and genitourinary cancers, emphasizing the need for disease-specific surveillance. Among breast cancer survivors, 10% to 40% develop lymphedema, with risk highest after axillary lymph node dissection and radiation compared with sentinel lymph node biopsy alone. Gynecologic cancer patients undergoing pelvic lymphadenectomy and radiation face a 20% to 40% risk, with some series reporting up to 37% incidence in the first year posttreatment.[7] Head and neck cancer patients treated with multimodality therapy experience lymphedema rates as high as 90%, often involving the face, neck, and intraoral tissues.[15] Sex-Based Differences and Population Trends Men more often develop lymphedema from trauma, infection, or chronic venous disease, whereas women are more commonly affected by cancer therapy–related lymphedema, suggesting sex-specific etiologic patterns. A nationwide South Korean analysis using the Health Insurance Review and Assessment (HIRA) database demonstrated a rising incidence of lymphedema and notable demographic variation by age and sex, highlighting its growing healthcare burden.[16]

Lymphedema is a form of low-output lymphatic failure, in which the lymphatic system's transport capacity is insufficient de spite normal capillary filtration. This distinguishes it from high-output edemas, such as those seen in cardiac or renal disease, where lymphatics are overwhelmed by excess fluid production.[2] Inflammation and Fibrosis Impaired lymph clearance initiates a chronic inflammatory cascade. Interstitial stasis attracts CD4 T cells—particularly Th2 subtypes—and macrophages, which release profibrotic cytokines including interleukin (IL)-4, IL-13, and tumor growth factor (TGF)-β1. These mediators drive fibroblast activation and extracellular matrix accumulation, leading to progressive tissue fibrosis.[17][18] Chronic inflammation compromises immune surveillance, increasing susceptibility to recurrent infections such as cellulitis and erysipelas. Adipose Tissue Remodeling Lymphedema is characterized not only by fibrosis but also by abnormal adipose deposition. Proinflammatory signaling promotes adipocyte hypertrophy and expansion, contributing to structural remodeling. Transcriptional changes linked to adipogenesis further perpetuate lymphatic dysfunction and tissue stiffness.[19] Lymphatic Pump Failure and Biomechanics Structural and functional damage to collecting lymphatic vessels, including valvular incompetence and smooth muscle dysfunction, impairs active lymph propulsion. These biomechanical failures contribute to fluid stagnation and progressive edema.[20] Lymphatic endothelial dysfunction also disrupts immune cell trafficking and antigen presentation, exacerbating local immune dysregulation.[21] Complications and Rare Sequelae Persistent immune suppression and tissue remodeling predispose patients to recurrent soft tissue infections. In rare, long-standing cases, lymphedema may progress to lymphangiosarcoma (Stewart-Treves syndrome), with an estimated incidence of 0.45% in postmastectomy patients and a poor prognosis.[22] Molecular and Experimental Insights

Persistent immune suppression and tissue remodeling predispose patients to recurrent soft tissue infections. In rare, long-standing cases, lymphedema may progress to lymphangiosarcoma (Stewart-Treves syndrome), with an estimated incidence of 0.45% in postmastectomy patients and a poor prognosis.[22] Molecular and Experimental Insights Animal models have replicated key features of human lymphedema, such as fibrosis, immune cell infiltration, and lymphatic remodeling. Recent studies have identified fibroblast subtypes associated with extracellular matrix changes and disease progression, offering potential therapeutic targets.[23] At the molecular level, chronic lymphedema is linked to sustained activation of the VEGF-C/VEGF receptor-3, TGF-β, and nuclear factor kappa-light-chain-enhancer of activated B cells pathways, reinforcing its classification as a fibroinflammatory disease.[24] Skin and Tissue Alterations Breast cancer–related lymphedema has been associated with skin barrier defects, including impaired epidermal differentiation and tight junction dysfunction, which exacerbate inflammation and infection risk.[25] Multi-omics analyses have further revealed metabolic and structural changes in affected adipose tissue, reinforcing the systemic impact of chronic lymphatic failure.[26] Emerging Therapeutic Mechanisms Targeted therapies aimed at modifying fibrotic remodeling are under investigation. Inhibition of uPARAP, a key regulator of extracellular matrix turnover, has shown promise in preclinical models by improving lymphatic architecture and reducing disease burden.[27] Device-based adjuncts, such as mechanical lymphatic stimulators, are also being evaluated for patients unresponsive to standard care, with early studies reporting favorable safety profiles. Gene therapy approaches, such as adenoviral delivery of VEGF-C, and cell-based therapies are being studied for their potential to promote lymphangiogenesis, although these remain investigational.[28] Differentiation from Lipedema Although often coexisting, lipedema is a distinct entity characterized by symmetric adipose tissue deposition with minimal lymphatic compromise in early stages. Unlike lymphedema, it typically spares the feet and presents without significant pitting edema.[29][30] Conclusion

Targeted therapies aimed at modifying fibrotic remodeling are under investigation. Inhibition of uPARAP, a key regulator of extracellular matrix turnover, has shown promise in preclinical models by improving lymphatic architecture and reducing disease burden.[27] Device-based adjuncts, such as mechanical lymphatic stimulators, are also being evaluated for patients unresponsive to standard care, with early studies reporting favorable safety profiles. Gene therapy approaches, such as adenoviral delivery of VEGF-C, and cell-based therapies are being studied for their potential to promote lymphangiogenesis, although these remain investigational.[28] Differentiation from Lipedema Although often coexisting, lipedema is a distinct entity characterized by symmetric adipose tissue deposition with minimal lymphatic compromise in early stages. Unlike lymphedema, it typically spares the feet and presents without significant pitting edema.[29][30] Conclusion The lymphatic system plays a critical role in fluid homeostasis and immune regulation. Disruption of its structure and function results in persistent inflammation, immune dysregulation, and irreversible tissue remodeling.

There is no single pathognomonic histologic feature of lymphedema; however, findings vary by disease stage and reflect its underlying fibroinflammatory pathogenesis. Early-Stage Changes Early lymphedema is marked by: Dermal edema, with expansion of the interstitial space due to protein-rich lymphatic fluid Dilated lymphatic vessels in the dermis and subcutis Minimal fibrosis, with limited inflammatory infiltrates [31] Chronic-Stage Changes With chronicity, histologic changes become more pronounced: Epidermal hyperplasia occurs, including hyperkeratosis, acanthosis, and papillomatosis with wart-like projections. Dermal fibrosis is characterized by thickened collagen bundles and increased fibroblast density, particularly in the upper dermis.[32] Vascular changes are evident, including telangiectatic blood vessels with thickened walls. Perilymphatic fibrosis develops, with disorganized extracellular matrix deposition around lymphatics and adipocytes. Adipose expansion occurs in longstanding disease and is characterized by adipocyte hypertrophy and subcutaneous fat accumulation. Immunologic and Molecular Findings Immunohistochemical analyses and murine models have revealed chronic infiltration by CD4 T lymphocytes and M2-polarized macrophages, localized near lymphatics and fibrotic regions.[33]These immune cells secrete Th2-associated cytokines such as IL-4, IL-13, and TGF-β1, driving fibrosis and adipogenesis.[5][34][35] In some cases, lymphatic endothelial hyperplasia may also be observed, though vessel function typically declines over time. Imaging-Histology Correlation Ultrasound and other imaging modalities often mirror histologic changes. Increased echogenicity reflects dermal fibrosis, while echo-free spaces correspond to interstitial fluid accumulation in the subcutaneous layer.[36] Diagnostic Considerations Histologic findings support the clinical assessment and correlate with disease progression. Thus, accurate evaluation begins with a thorough patient history and physical examination.

Accurate diagnosis of lymphedema requires a combination of clinical history, physical examination, objective measurements, and, when indicated, imaging. Early identification is essential to prevent irreversible fibroadipose tissue remodeling, functional decline, and complications like recurrent cellulitis. History A detailed history can help distinguish primary from secondary lymphedema: Onset and duration Gradual or sudden onset; latency from triggering events Family history Relevant for primary lymphedema, which may follow autosomal dominant inheritance with incomplete penetrance [3] Cancer history Especially breast, melanoma, pelvic, and head and neck cancers with surgery or radiation Surgical/traumatic injury Includes lymphadenectomy, orthopedic procedures, or burns Recurrent infections Episodes of cellulitis or erysipelas Foreign travel Exposure to filariasis-endemic regions Comorbidities Congestive heart failure, renal or hepatic disease, hypothyroidism (can contribute to generalized edema) Symptoms Heaviness, tightness, restricted motion; “pain is generally mild unless secondary infection, such as cellulitis, is present” Physical Examination Lymphedema typically presents as chronic, asymmetric swelling beginning distally. Key findings include: Stemmer sign Inability to pinch the skin at the base of the second toe or finger (pathognomonic) [37] Edema pattern Pitting in early stages; becomes nonpitting as fibrosis advances Skin changes Hyperkeratosis, papillomatosis, lymphangiomas, peau d’orange Distribution clues Primary lymphedema often involves the feet (lipedema spares them) Syndromic features Webbed neck (Turner), port-wine stains (Klippel-Trénaunay), hypoplastic nails Functional impact Reduced joint range, gait changes, and impaired activities of daily living in advanced disease

Quantitative Assessment Objective tools enhance diagnostic accuracy and longitudinal tracking.[38] They include: Circumferential measurements Measurements of ≥2 cm or ≥200 mL volume difference between limbs are significant. Volume estimation This is achieved via truncated cone formulas, perometry, or 3-dimensional (3D) infrared scanning. Bioimpedance spectroscopy (BIS) BIS detects extracellular fluid shifts. An L-Dex change >6.5 to 7.5 units indicates subclinical lymphedema.[39][40][41] BIS enables early detection and risk stratification, improving long-term outcomes.[42] Some centers have adopted preoperative BIS measurements to establish fluid baselines in cancer patients before lymphadenectomy, improving early detection of subclinical changes.[43][44] Imaging Modalities Imaging supports diagnosis in uncertain cases and surgical planning.[45] They include: Duplex ultrasonography Excludes deep vein thrombosis; differentiates venous causes Lymphoscintigraphy Functional gold standard showing dermal backflow and delayed tracer clearance Indocyanine green (ICG) lymphography Real-time mapping of superficial lymphatics [46][47] Magnetic resonance lymphangiography (MRL) Visualizes deep lymphatic channels and soft tissue changes [39] Contrast-enhanced ultrasound (CEUS) fusion Combines with magnetic resonance imaging (MRI) and computed tomography (CT) to aid microsurgical targeting Multimodal imaging Combinations (eg, ICG + MRL) improve diagnostic clarity in complex cases.[48] Special Considerations Head and neck lymphedema (HNL) Subtle early signs make diagnosis challenging. Near-infrared fluorescence lymphography and high-frequency ultrasound improve detection. A 2025 Delphi study noted global variability in HNL criteria, underscoring the need for standardization.[49] Genital and lower abdominal lymphedema Often underrecognized, symptoms like fullness or pressure may precede swelling. Emerging diagnostics Artificial intelligence (AI)-driven image analysis, biosensors, and elastography are being investigated to detect early or subclinical disease. Risk stratification Validated models and nomograms now guide surveillance strategies in high-risk populations (eg, postcancer surgery).

Lymphedema is chronic and progressive, requiring a multimodal approach. While curative options are limited, early and individualized treatment significantly improves outcomes.[50] Conservative (Nonsurgical) Management The primary therapeutic strategy for managing lymphedema is complex decongestive therapy (CDT), which is typically delivered in 2 phases.[51][52] Phase I (intensive phase) includes MLD, multilayer compression bandaging, skin care, and decongestive exercises.[53][54][55] Phase II (maintenance phase) focuses on long-term self-management through continued use of compression garments, exercise, skin hygiene, and self-administered MLD.[56][57] Originally developed and refined in Europe and later introduced to the United States in the early 1990s, CDT remains the primary treatment approach for stage II and III lymphedema. The effectiveness of this treatment has been widely demonstrated across clinical settings worldwide. Recent study results confirm that CDT reduces limb volume and improves functional status.[52][58] Additional conservative strategies include: Compression therapy: This is essential at all stages.[59] Adjustable wraps offer better adherence for some patients.[60] Exercise Supervised resistance training improves limb function without increasing lymphedema risk.[20][21][61][62] Pneumatic compression devices This serves as an adjunct during the maintenance phase. Adjunctive therapies Low-level laser therapy and Kinesio taping may offer mild symptom relief.[53] Filariasis-related care In endemic regions, treatment includes antifilarial drugs such as diethylcarbamazine or ivermectin, hygiene, compression, and exercise, often delivered via community programs.[59] Medical Management Supportive medical therapy includes: Antibiotics For cellulitis prevention and treatment Topical agents Keratolytics (eg, urea) or tacrolimus for papillomatosis Analgesics For discomfort flares Prophylactic compression Increasingly used immediately post-lymphadenectomy to prevent progression

In endemic regions, treatment includes antifilarial drugs such as diethylcarbamazine or ivermectin, hygiene, compression, and exercise, often delivered via community programs.[59] Medical Management Supportive medical therapy includes: Antibiotics For cellulitis prevention and treatment Topical agents Keratolytics (eg, urea) or tacrolimus for papillomatosis Analgesics For discomfort flares Prophylactic compression Increasingly used immediately post-lymphadenectomy to prevent progression Recent expert consensus supports its use as part of early risk-reduction strategies in high-risk patients, particularly following breast cancer surgery. Although the Food and Drug Administration has not approved any pharmacologic agents for lymphedema, investigational therapies such as ketoprofen have demonstrated anti-inflammatory effects and potential volume reduction in small trials. These agents target pathways like leukotriene signaling and oxidative stress and may offer future adjunctive options. Surgical Management The goal of excisional treatment of lymphedema is to remove the deposited fibrofatty tissue using either liposuction or resection. Liposuction is particularly effective in the upper extremity and has few adverse effects. Individuals with lymphedema treated with liposuction have a substantial long-term decrease in limb volume and improved quality of life when used alongside compression garments. Radical resection is a treatment option used only after failure of other treatments, and is much more likely to result in substantial morbidity due to the increased level of invasiveness. Surgical options are reserved for refractory or advanced disease and include: Lymphovenous anastomosis (LVA) and lymphaticovenous bypass (LVB) Microsurgical diversion of lymph into venous circulation [26] Vascularized lymph node transfer (VLNT) Autologous transfer of lymph node–bearing tissue to reestablish drainage [63][64] Suction-assisted protein lipectomy (SAPL) Liposuction-based removal of fibroadipose tissue in chronic lymphedema [65] Preventive LVA, such as the lymphatic microsurgical preventive healing approach (LYMPHA) Involves immediate lymphatic reconstruction during cancer surgery and has been shown to reduce the incidence of lymphedema.[52][65][66][67] Sentinel lymph node biopsy This is now preferred over full dissection to reduce risk. Advanced technologies

Preventive LVA, such as the lymphatic microsurgical preventive healing approach (LYMPHA) Involves immediate lymphatic reconstruction during cancer surgery and has been shown to reduce the incidence of lymphedema.[52][65][66][67] Sentinel lymph node biopsy This is now preferred over full dissection to reduce risk. Advanced technologies Super microsurgery, robotic assistance, and near-infrared imaging enhance surgical precision and accessibility. Patient-Specific Strategies and Surgical Innovations Breast cancer–related lymphedema Management includes CDT, compression, LYMPHA during axillary surgery, and survivorship education.[68][69][70][71] HNL Requires tailored therapy including compression garments and, in select cases, LVA or VLNT [61] Elective surgery on affected limbs May proceed with precautions (eg, infection prophylaxis, minimal tourniquet use) Precision care Advanced imaging, wearable sensors, and patient-specific physiotherapy regimens support a shift toward personalized, survivorship-centered management. Evidence-Based Practice and Long-Term Outcomes Key best practices to optimize lymphedema outcomes include the following: Surveillance and early detection High-risk individuals, such as those postmastectomy, should be monitored regularly using tools like BIS or perometry. Early identification enables timely intervention before significant edema develops.[72][73] Tailored compression Compression therapy must be individualized. Proper fitting and routine reassessment are crucial as limb size and shape change. Adjunct therapies Some patients benefit from additional modalities such as kinesiotaping, low-level laser therapy, myofascial release, or pneumatic compression. These can be integrated into care plans on a case-by-case basis. Adherence support Ongoing education, psychosocial support, and regular follow-up improve long-term adherence to compression and self-care.[71] Postoperative care For those undergoing lymphedema surgery, coordinated postop management (compression, physical therapy, psychosocial support) is vital to optimize outcomes and prevent relapse.

Lymphedema must be distinguished from other causes of localized or generalized edema. A systematic approach includes evaluating systemic and local/regional conditions with overlapping clinical presentations. Differential Diagnosis of Lower Extremity Edema Lipedema Lipodystrophy, most common in obese women Causes symmetrical enlargement of calves and thighs Feet spared, unlike lymphedema May show pitting edema Venous insufficiency Hydrostatic cause of leg edema Associated with cutaneous changes, such as hemosiderin deposits Role determined by history and clinical context Lymphatic–venous interaction Venous hypertension can increase lymphatic load, causing secondary lymphedema. Many patients present with mixed lymphatic–venous edema. This is also known as “phlebolymphedema.” Systemic Causes Congestive heart failure Nephrotic syndrome or glomerulonephritis Hepatic cirrhosis with anasarca Hypoproteinemia, including that from severe malnutrition Drug-induced edema (eg, calcium channel blockers) Thyroid disease, especially Graves' disease with pretibial myxedema Constrictive pericarditis Local/Regional Causes Deep vein thrombosis: Acute, often unilateral swelling Chronic venous insufficiency: Stasis edema with hemosiderin skin changes Lipedema: Symmetric adipose accumulation in the lower extremities, sparing the feet; minimal pitting [74] Baker cyst: Posterior knee mass with referred calf swelling Dependency edema: Improves with limb elevation Cellulitis: Painful, erythematous edema with systemic signs Malignancy: Tumor-related obstruction of lymphatics or veins Postsurgical edema: Transient, resolves with healing Arthritis-related joint swelling: May involve adjacent soft tissues Key Distinguishing Features Important clinical clues include: Laterality Lymphedema is often unilateral; lipedema and systemic edema are typically bilateral. Pitting Lymphedema begins with pitting, which resolves as fibrosis progresses. Lipedema shows little to no pitting early. Foot involvement Lymphedema affects the feet; lipedema spares them. Response to elevation or diuretics Lymphedema is less responsive than venous or dependent edema. Skin findings Hyperkeratosis and papillomatosis in lymphedema; stasis dermatitis in venous disease. Imaging Duplex ultrasound, lymphoscintigraphy, and MRI aid differentiation.

Foot involvement Lymphedema affects the feet; lipedema spares them. Response to elevation or diuretics Lymphedema is less responsive than venous or dependent edema. Skin findings Hyperkeratosis and papillomatosis in lymphedema; stasis dermatitis in venous disease. Imaging Duplex ultrasound, lymphoscintigraphy, and MRI aid differentiation. In rare cases, inherited lymphatic syndromes (eg, Hennekam lymphangiectasia–lymedema syndrome) present with limb swelling and associated organ involvement, such as intestinal lymphangiectasia or pleural/pericardial effusions. These require broader systemic evaluation. Lipedema is frequently misdiagnosed as lymphedema. This condition presents with symmetrical lower limb fat deposition sparing the feet, minimal early pitting, and typically no history of infection or skin changes. Lipedema is often associated with pain or tenderness and predominantly affects women.[29][75][76] HNL may be mistaken for other causes of facial or cervical swelling and often presents with subtle or atypical features. This type requires specialized evaluation techniques and clinician awareness to avoid misdiagnosis.[49]

Staging of Lymphedema The International Society of Lymphology (ISL) classifies lymphedema into 4 clinical stages that reflect the chronicity and progression of lymphatic dysfunction. Accurate staging is essential for guiding treatment and prognosis. Stage 0 (latency/subclinical stage) Lymphatic transport is impaired, but no visible or palpable edema is present. The limb is “at risk,” particularly after lymph node dissection or radiation. Imaging such as lymphoscintigraphy or ICG lymphography may detect reduced lymphatic flow.[4][46][77][78] This stage may persist for months or years without clinical progression. Stage I (spontaneously reversible lymphedema) Marked by soft, pitting edema that often develops throughout the day and typically subsides with limb elevation or overnight. Fibrosis is minimal or absent. Swelling usually begins distally (eg, hand or foot) and may fluctuate. Conservative therapy (eg, compression and CDT) is often effective.[1] Stage II (spontaneously irreversible lymphedema) Edema persists despite elevation and becomes less reversible over time. Fibrotic tissue changes (induration) become apparent. Pitting may be present early but becomes increasingly difficult to elicit as fibrosis advances. Skin changes such as hyperkeratosis and papillomatosis may emerge. Clinicians often describe early vs late stage II based on persistence of pitting and severity of fibrosis, though this is not a formal ISL subdivision. Stage III (lymphostatic elephantiasis) Extensive, nonpitting swelling, significant fibrosis, skin thickening, papillomatosis, and deep cutaneous folds are common (see Image. Stage 3 Lymphedema of the Bilateral Lower Extremities). Functional impairment and recurrent infections (eg, cellulitis) are also common. This typically occurs in long-standing, untreated cases like advanced filarial lymphedema. ISL 2020 Severity Grading by Limb Volume In addition to clinical staging, the ISL recommends grading severity based on the limb volume difference relative to the contralateral normal limb.[50][79] Mild: >5% to <20% volume increase Moderate: 20% to 40% volume increase Severe: >40% volume increase The ISL staging system is endorsed by the American Physical Therapy Association (APTA) and the American Venous Forum (AVF) and remains the clinical standard for evaluating and managing lymphedema.[4][80][81]

Lymphedema is a chronic condition with variable outcomes, influenced by its cause, diagnostic severity, and adherence to therapy. Early-stage disease, particularly ISL stage 0 or I, responds well to timely intervention, including CDT, compression, and risk reduction strategies.[58] In contrast, advanced stages with fibrofatty tissue changes are more resistant to reversal and often result in lasting pain, functional decline, and infection risk.[2][82] Cancer-related lymphedema carries a lifelong risk and may emerge years after oncologic treatment. While not curable, consistent use of compression garments, guided physical therapy, and, when appropriate, surgical interventions can help stabilize symptoms and prevent deterioration.[61][83] Head and neck lymphedema may improve with therapy, but often persists and impacts speech, swallowing, and appearance. If left untreated, lymphedema can lead to recurrent cellulitis, progressive fibrosis, and significant psychosocial burden. However, early identification, patient participation in care, and multidisciplinary coordination are associated with better long-term function and reduced complications.[58] Individuals with lymphatic and complex vascular malformations commonly exhibit peripheral lymphedema as a key clinical feature. Treatment has increasingly advanced into the molecular field, with mechanistic target of rapamycin inhibitors employed to stabilize and improve vascular abnormalities. Furthermore, results from emerging studies suggest that targeted small-molecule agents that modulate specific cellular pathways may provide effective new therapies for these patients.

Lymphedema is associated with multiple medical and psychosocial complications: Cellulitis and erysipelas Recurrent infections are common and may worsen lymphatic damage. Lymphangitis and lymphangioadenitis Inflammation of lymphatic vessels and nodes often follows infection. Superficial infections Fungal (eg, intertrigo, dermatophytosis) and bacterial skin infections are frequent. Deep vein thrombosis This may occur due to immobility or be confused with lymphedema. Functional impairment Chronic swelling limits mobility and daily activities. Psychosocial effects Depression, anxiety, and body image issues are prevalent. Cosmetic disfigurement Progressive fibroadipose changes cause visible deformity. Lymphangiosarcoma A rare, aggressive malignancy that can be found in chronic, untreated cases. Amputation This is rarely required for intractable infection or malignant transformation. Postsurgical complications include partial wound separation, seroma, hematoma, skin necrosis, lymphatic leaks, and infection—especially in irradiated or high-risk tissue beds.

The following consultations may be needed: Oncology: For cancer-related lymphedema or suspected recurrence. Infectious disease: For recurrent cellulitis or complex infections. Certified lymphedema therapist: For comprehensive rehabilitation, including manual drainage and compression. Vascular or plastic surgery: For surgical candidates (eg, LVA, VLNT, liposuction). Dermatology: For chronic skin changes or suspected lymphangiosarcoma. Mental health: For psychological support related to disfigurement or disability.

Lymphedema is swelling that can occur after cancer treatment, particularly when lymph nodes have been removed or treated with radiation. Risk increases with lymph node surgery or radiation, infections or injuries, excess body weight, and lack of movement. To help lower risk, patients should begin gentle activity about a week after surgery (if their clinician approves), a healthy weight should be maintained, and their skin should be protected by keeping it clean and moisturized while avoiding cuts, bites, and burns. Compression sleeves or stockings should be recommended (if the care team approves), and pressure or injury to the affected area should be prevented by steering clear of tight clothing, blood draws, or blood pressure cuffs on that side. Patients should limit heat exposure by avoiding hot tubs and saunas and practicing self-care, such as learning simple massage techniques or using virtual rehabilitation resources when available. They should also watch closely for early signs, such as swelling, a feeling of heaviness or tightness, or clothes and rings becoming tighter on one side, and should contact their care team promptly if these occur. If swelling begins, early treatment is most effective and may include compression garments, special exercises, gentle massage, and complete care by a trained therapist. Effective long-term lymphedema management relies heavily on patient education and consistent self-care. Patients should learn simplified MLD (eg, self-MLD) techniques to maintain lymph flow during the maintenance phase and practice meticulous infection prevention through careful skin care, hygiene, regular moisturization, and prompt cellulitis treatment.[84] Regular aerobic and resistance exercise, ideally under professional guidance, helps improve lymphatic return and overall function without worsening lymphedema. Because obesity is a modifiable risk factor, weight loss can improve outcomes and reduce limb volume. Proper use of compression garments is another key management component; patients should be trained in the correct application, removal, and care of compression garments or wraps to ensure consistent use. Preventive measures to avoid limb constriction include avoiding tight clothing or jewelry and blood draws or blood pressure measurements on the affected side.

Because obesity is a modifiable risk factor, weight loss can improve outcomes and reduce limb volume. Proper use of compression garments is another key management component; patients should be trained in the correct application, removal, and care of compression garments or wraps to ensure consistent use. Preventive measures to avoid limb constriction include avoiding tight clothing or jewelry and blood draws or blood pressure measurements on the affected side. Psychosocial support is also essential, as patients often face body image issues, anxiety, and the ongoing burden of chronic care. Peer support groups, national lymphedema networks, and standardized educational materials can help patients cope and remain engaged in their care. However, recent analyses show that online patient education materials, including short-form videos on social media, vary widely in quality, accuracy, and readability, highlighting the need for reliable, patient-centered content. Lymphedema patients report higher rates of depression and lower quality of life compared with those who have lipedema, underscoring the significant psychosocial impact of chronic lymphatic dysfunction. In addition, the financial burden—such as the cost of compression garments and therapy—can limit adherence, particularly in lower-resource settings.[71][85]

Effective lymphedema care requires a coordinated, multidisciplinary strategy in which clinicians, nurses, therapists, pharmacists, and mental health professionals collaborate to deliver patient-centered, evidence-based management. A strong interprofessional approach improves outcomes by addressing care's physical, psychological, and educational aspects.[72] Primary care clinicians are key in early recognition, patient education, and timely referral to lymphedema specialists.[71][73] Surgeons and oncologists implement preventive measures during cancer treatment—such as minimally invasive lymph node staging and, when appropriate, immediate lymphaticovenous anastomosis—and refer high-risk individuals for surveillance. Certified lymphedema therapists provide complete decongestive therapy, fit compression garments, and train patients in self-management techniques. At the same time, nurses and wound care specialists manage skin integrity problems (including lymphorrhea and ulcers), monitor for infections, and reinforce education on meticulous skin care.[86] Physical and occupational therapists focus on improving limb function and range of motion and developing adaptive strategies to support daily activities and return to work. Pharmacists counsel on medications that may influence edema, assist with antibiotic prophylaxis plans when indicated, and encourage adherence to compression therapy. Mental health professionals address depression, anxiety, and self-image concerns related to lymphedema and provide counseling or therapy as needed.

At the same time, nurses and wound care specialists manage skin integrity problems (including lymphorrhea and ulcers), monitor for infections, and reinforce education on meticulous skin care.[86] Physical and occupational therapists focus on improving limb function and range of motion and developing adaptive strategies to support daily activities and return to work. Pharmacists counsel on medications that may influence edema, assist with antibiotic prophylaxis plans when indicated, and encourage adherence to compression therapy. Mental health professionals address depression, anxiety, and self-image concerns related to lymphedema and provide counseling or therapy as needed. Across these disciplines, clear communication and structured care coordination are critical to enhancing patient safety and outcomes. Clinicians guide diagnosis and long-term treatment planning; nurses and therapists ensure patients understand and can implement skin care, exercise, and compression strategies; and pharmacists and mental health professionals support medical and psychosocial aspects of care. Regular interprofessional meetings, shared electronic health records, and standardized handoff protocols help the team recognize complications, such as infections or worsening edema, early and respond promptly. This collaborative model fosters patient engagement, supports adherence to self-management, and integrates education and psychosocial support, thereby improving quality of life, reducing complications, and strengthening overall team performance in lymphedema management.